Navigation Links
Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System
Date:4/3/2011

alized medicine.

ABOUT REG1, REG2 and REG3  

Regado's lead program, the anticoagulant system REG1, consists of two parenteral agents both administered by IV bolus, the first being a potent highly selective Factor IXa inhibitor (pegnivacogin, a.k.a. RB006) and the second being its complementary active control agent (anivamersen, a.k.a. RB007).  Anivamersen can be used to selectively completely or partially reverse the anticoagulant effect of pegnivacogin.  REG1, having recently completed phase 2b clinical development (the RADAR trial), is intended for application in arterial thrombosis indications, such as Acute Coronary Syndrome patients undergoing Percutaneous Coronary Intervention.  A clinical program in Open Heart Surgery [including coronary artery bypass grafting (CABG) and valve repair/replacement] is also under development.  REG2, Regado's second product candidate, consists of a subcutaneously administered depot formulation of pegnivacogin paired with the IV bolus formulation of anivamersen.  REG2 recently completed single escalating dose phase 1 clinical testing (the first successful subcutaneous application of an aptamer in humans) and is planned to be studied in a multiple escalating dose clinical trial in 2011.  It is intended for use in venous thrombosis indications such as venous thromboembolism (VTE) prophylaxis in patients undergoing abdominal surgery.  REG3, Regado's third program, consists of a specific GPVI inhibitor and its active control agent (RB571 and RB515, respectively).  REG3 is planned to enter phase 1 human clinical testing in 2011 and will be indicated for antiplatelet therapy.  Information pertaining to Regado's clinical programs may be obtained at www.clinicaltrials.gov.

ABOUT APTAMERS

Pegnivacogin is a member of a class of compounds called aptamers.  Aptamers are single stranded oligonucleotides
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Regado Biosciences to Present at the Needham & Companys 10th Annual Healthcare Conference in New York City
2. Regado Biosciences, Inc. Announces Presentation of the Results of the RADAR Phase 2b Clinical Trial of Its Anticoagulant System REG1 at the i2 Summit During the American College of Cardiology 2011 60th Annual Scientific Session & Expo in New Orleans
3. Regado Biosciences to Present at the 2011 RBC Capital Markets Healthcare Conference in New York City
4. Regado Biosciences, Inc. Introduces REG3, a Novel Aptamer-Based Inhibitor of Glycoprotein VI and its Matched Active Control Agent, at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
5. Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
6. Regado Biosciences, Inc. Presents Two Abstracts on the Subcutaneous Depot Formulation of Pegnivacogin, a Nuclease-Stabilized RNA Aptamer, Direct Factor IXa Inhibitor and Part of the REG2 Anticoagulant System, at the American Heart Association (AHA)
7. Regado Biosciences to Present at the IMPACT 2010 Conference in Philadelphia, Pennsylvania
8. Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010
9. Regado Biosciences to Present at the Stifel Nicolaus Healthcare Conference 2010 on September 16, 2010 in Boston, Massachusetts
10. Regado Biosciences to Present at the 2010 Wells Fargo Healthcare Conference on June 24, 2010 in Boston, Massachusetts
11. Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... , Dec. 19, 2014   Hospira, Inc. ... provider of injectable drugs and infusion technologies, today announced ... 33rd Annual Healthcare Conference on Wednesday, Jan. 14, 2015, ... is scheduled to begin at 10:30 a.m. Pacific time ... to all interested parties through a live audiocast accessible ...
(Date:12/19/2014)... N.C. , Dec. 19, 2014 ... consumer research and marketing communication tools are essential ... globally competitive – consequently consumers, desires, preferences, and ... this environment, market research groups across all industries ... marketing communication tools. However, the adoption of new ...
(Date:12/19/2014)... CARDIFF-BY-THE-SEA, Calif. , Dec. 19, 2014 ... ;  Sorrento), an oncology company developing new treatments ... a privately-held immuno-oncology company developing proprietary Neukoplast ® ... therapy, announced today that the companies have entered ... generation CAR-TNK™ (pronounced as "Car-Tank") immunotherapies for the ...
Breaking Medicine Technology:Study Uncovers New Tools and Techniques for Understanding Consumer Decision Making 2Sorrento and Conkwest Announce Exclusive Global Collaboration 2Sorrento and Conkwest Announce Exclusive Global Collaboration 3Sorrento and Conkwest Announce Exclusive Global Collaboration 4Sorrento and Conkwest Announce Exclusive Global Collaboration 5
... Texas, Oct. 12 Researchers at Texas State University-San ... and anti-retroviral compound with promising results. , Dhiraj Vattem, ... and Reed Richardson, professor in the Department of Agriculture, ... Results were announced at a University press conference. ...
... Oct. 12 RSB Spine, LLC, today announced that the ... reclassification of interbody fusion devices occurred in 2007, the C-Ti ... Drug Administration. With this most recent announcement, the C-Ti ... cleared as an anterior cervical plate as well. , RSB ...
Cached Medicine Technology:Texas State Tests Potential New Cancer-Fighting Weapon 2
(Date:12/19/2014)... It’s very easy to become overwhelmed with ... put to the wayside until Christmas and the New Year ... “itch” and that burning desire to just escape it all ... journey to Telluride with a no-fuss, affordable package. Montrose Days ... the resort, and ensure that all accommodations are met. Plus, ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 Sub Zero Ice ... sponsor a blood drive Sunday the 28th from 2pm-6pm at ... & Sawyer Road in Sarasota, FL. , Inquiries regarding time ... you for participating in the donating process, Sub Zero Ice ... flash frozen, custom ice cream. , About Sub Zero Ice ...
(Date:12/19/2014)... The Plantrician Project , ... events, tools and resources for healthcare professionals and ... the world’s leading online cooking school, have joined ... needs: Culinary Rx. As an online food and ... scheduled for debut spring 2015, will be designed ...
(Date:12/19/2014)... Rosa, CA (PRWEB) December 19, 2014 ... and 5x5 SuperClone Rooms. SuperCloset continues to offer indoor ... solutions. Pair one of the new SuperClone Rooms with ... professional, perpetual, and turnkey indoor hydroponic grow room setup. ... in the world, SuperCloset’s SuperPonic SuperCloner 50 . ...
(Date:12/19/2014)... These vanadium reserves are mostly found in China, ... of vanadium were produced globally in 2013, up 11% ... 6.7% AAGR during the period from 2001 to 2013, ... largest consumer, accounted for more than 90% of total ... the chemical industry. , View Full Report at ...
Breaking Medicine News(10 mins):Health News:Days Inn Montrose Colorado Delivers Last Minute Holiday Season Ski Getaway Accommodations 2Health News:Shark Tank’s Sub Zero Ice Cream Sponsors Blood Drive 2Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 2Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 3Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 4Health News:SuperCloset Continues to Innovate with New Complete Indoor Grow Room Packages, The SuperClone Rooms are the Newest Addition to the Award Winning SuperRoom Lineup 2Health News:Marketresearchreports.biz: Global Vanadium Usage Increased at AAGR of 6.7% between 2001 and 2013 2Health News:Marketresearchreports.biz: Global Vanadium Usage Increased at AAGR of 6.7% between 2001 and 2013 3
... from NewYork-Presbyterian Hospital/Weill Cornell Medical Center will present ... Association,s Annual Meeting in San Francisco, May 29 ... a urologist and professor of urology at NewYork-Presbyterian ... senior author and professor emeritus of urology at ...
... A minimally invasive technique used to destroy kidney tumors ... as surgical removal of tumors in curbing cancer recurrence ... In an article available online in the journal ... radiology at UT Southwestern Medical Center, reported the outcomes ...
... (BRONX, NY) The National Institutes of Health ... Medicine of Yeshiva University a five-year, $3.9 million grant ... in rural South Africa. The findings could alter public ... developing world. "Most cases of XDR-TB are thought ...
... ... demanding enterprise customers with VMware and Microsoft Hyper-V environments. , ... (PRWEB) June 2, 2010 -- VKernel, the ... announced today the general availability of VKernel Optimization Pack 1.4. The latest version ...
... aggressive ones, found in heaviest men, study says , WEDNESDAY, ... patients appears to be linked to patient weight, with heavier ... The finding stems from work involving more than 3,300 prostate ... surgery between 2001 and 2007 to remove a malignant prostate ...
... Risk aversion isn,t inevitable part of aging, researchers find ... says older people make less risky -- and less ... otherwise. , In some cases, older people make just ... people, researchers report. , "It,s not age, per se, ...
Cached Medicine News:Health News:NewYork-Presbyterian/Weill Cornell physician-scientists present at 2010 American Urological Meeting 2Health News:NewYork-Presbyterian/Weill Cornell physician-scientists present at 2010 American Urological Meeting 3Health News:Ablation proved as effective as traditional surgery in treating kidney cancer 2Health News:Einstein awarded NIH grant to study drug-resistant TB 2Health News:Einstein awarded NIH grant to study drug-resistant TB 3Health News:VKernel Raises Scalability and Reporting Bar with Optimization Pack 1.4 2Health News:Size of Prostate Tumor Linked to Patients' Weight 2Health News:Grandpa's Decision-Making Skills May Be Just Fine 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: